Caris Life Sciences has launched the roadshow for its proposed initial public offering of its common stock.
The initial public offering price is expected to be between $16 and $18 per share. It plans to offer 23,529,412 shares of its common stock to the public, while granting the underwriters a 30-day option to purchase up to an additional 3,529,411 shares.
Caris has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol “CAI."
Caris Life Sciences specializes in molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms. The company has created a multimodal clinico-genomic database and computing capability for analyzing the molecular complexity of disease.
The company's platform is built for developing precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
